Genetic Technologies Limited · ASX:GTG

Genetic Technologies — AusBiotech 2011 National Conference

11 slides from Genetic Technologies's conference presentation, Oct 19, 2011

  1. Slide 1: Presentation at AusBiotech 2011 National Conference

    For personal use only ASX ANNOUNCEMENT October 19th, 2011 ___________________________________________________________________________________ Presentation at AusBiotech 2011 National Conference Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) advises that the Company is attending the AusBiotech

  2. Slide 2: Highlights

    GENETIC TECHNOLOGIES LIMITED For personal use only (ASX:GTG; NASDAQ: GENE) Highlights ƒ Established molecular diagnostics business with global reach ƒ 1st US focused cancer diagnostic launched June 2011 ƒ Supported by in‐house US sales and marketing capability ƒ Targeting accretive growth in cancer

  3. Slide 3: Forward Looking Statements

    For personal use only Forward Looking Statements This presentation may contain forward‐looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach

  4. Slide 4: Snapshot

    For personal use only Snapshot ƒ Profitable and cash flow positive financial year 2010/11 ƒ $18.3M revenues, $900k profit, $2.2m positive cash ƒ Currently in the 2nd year of a 5 year strategy to build a global cancer diagnostics business ƒ BREVAGen™ is the first product in this expansion ƒ June 2011

  5. Slide 5: Oncology Focus

    Oncology Focus ƒ New technologies driving For personal use only targeted interventions & extending lives ƒ Demography and healthcare costs driving growth ƒ Molecular diagnosis of cancer is most attractive segment of the Dx industry ƒ Focused market & efficient sales process ƒ Strong accelerating gro

  6. Slide 6: Portfolio Strategy

    For personal use only Portfolio Strategy Gen1 in validation Colorectal / Uterine Cancer KRas Launched 2006 BRaf EGFR 2004 PacRim launch Gen2 in evaluation with pharma partner KRas June 2011 US launch Jun 2011 US launch BRaf EGFR ƒ Developing a portfolio of tools across cancer management spectrum ƒ B

  7. Slide 7: BREVAGen™

    For personal use only BREVAGen™ ƒ Novel, validated test for non‐familial breast cancer risk, published JNCI Oct2010 ƒ US$600m per annum US market opportunity ƒ Attractive gross margin ‐cheek swab ƒ Launched in 8 initial US territories June2011 ƒ High profile Key Opinion Leaders involved ƒ Experts at

  8. Slide 8: BREVAGen™: What does it Mean Clinically?

    For personal use only BREVAGen™: What does it Mean Clinically? ƒ BREVAGen™ classifies a woman’s 5 year & lifetime risk of non‐ familial breast cancer, the commonest variety ƒ Test combines population risk factors with 7 genetic biomarkers (SNPs) to give an integrated, individual breast cancer risk a

  9. Slide 9: Product Portfolio

    For personal use only Product Portfolio Target Discovery Clinical Regulatory and Validation Review Launch and Selection Studies or CLIA Release Marker Clinical Launch Claim Validation Utility Planning Extension Studies & Studies Publication BRCA/HNPCC/SCN1A (EU/PacRim) BREVAGEN™ Theranostic markers

  10. Slide 10: Licensing: Non-Dilutive Funding Source

    For personal use only Licensing: Non‐Dilutive Funding Source ƒ Non‐coding DNA patent estate is one of GTG’s core assets ƒ 60+ licenses, $65m+ revenue received to date ƒ 9 Licenses granted FY2011 to date for total $14m ƒ Contracted annuity stream of $5.5m in total to 2015 ƒ Foundational patent famili

  11. Slide 11: Financial Snapshot June 2011

    For personal use only Financial Snapshot June 2011 Financials (12 months to Jun30) Share Register (AUD millions) 2011 2010 ƒ Shares outstanding 464.6m Revenue 18.3 8.7 Top 20 shareholders 76% Operations* 4.6 4.9 Total shareholders 2,850 Licensing 13.7 3.8 ƒ Options outstanding ** 20.7m Net income /

Genetic Technologies — AusBiotech 2011 National Conference on 6ix